1. Endrenyi L, Declerck P, Chow SC. Biosimilar Product Development. London: Taylor & Francis; 2017.
2. BPCI. Biologic price, competition, and innovation act. Washington DC: United States Congress; 2009.
3. FDA. Guidance on Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Silver Spring: The United States Food and Drug Administration; 2015.
4. FDA (2017, 2019). Guidance for industry—considerations in demonstrating interchangeability with a reference product. The United States Food and Drug Administration, Silver Spring.
5. Chow S, Song F, Cui C. On hybrid parallel–crossover designs for assessing drug interchangeability of biosimilar products. J Biopharm Stat. 2017;27:265–71.